Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) was up 4.1% during mid-day trading on Wednesday . The stock traded as high as $2.11 and last traded at $2.05. Approximately 184,975 shares changed hands during trading, a decline of 70% from the average daily volume of 620,672 shares. The stock had previously closed at $1.97.
Cortexyme Trading Up 4.1 %
The company has a market cap of $61.81 million, a price-to-earnings ratio of -0.69 and a beta of 1.40. The stock’s fifty day simple moving average is $1.44 and its 200 day simple moving average is $0.98.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Recommended Stories
- Five stocks we like better than Cortexyme
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Great CPU Race: AMD and Intel Battle for Dominance
- Comparing and Trading High PE Ratio Stocks
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Best Stocks Under $5.00
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
